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Apolipoprotein A-I Therapy
Promise, Challenges, and Disappointment*
Michael H. Davidson, MD
Chicago, Illinois
Since 1988, with the release of the National Cholesterol
Education Panel (NCEP) Adult Treatment Panel I, low-
density lipoprotein cholesterol (LDL-C) has been the
primary focus of therapy (1). Although the total cholesterol
to high-density lipoprotein cholesterol (HDL-C) ratio is a
better cardiovascular risk predictor (2), the consensus at the
time was that the clinical evidence only supported LDL-C
reduction to improve outcomes. For the past 20 years,
targeting LDL-C has yielded impressive results, especially
with statins, yet low HDL-C continues to predict increased
cardiovascular events, even in conjunction with low LDL-C
levels (3). High LDL-C and low HDL-C are approxi-
mately equal risk factors in population studies, and both
lipoproteins are causally linked to atherosclerosis (4). Severe
apolipoprotein (apo) A-I deficiency (familial hypoalphali-
poproteinemia) is associated with very premature coronary
heart disease similar to heterozygous familial hypercholes-
terolemia (5). However, unlike LDL metabolism, in which
the cellular regulation is well understood, HDL and the
process of reverse cholesterol transport remain complex and
elusive targets of drug development (6).
See page 1111
The process of reverse cholesterol transport involves the
efflux of free cholesterol in the macrophage to discoidal
pre–1-HDL. Discoidal pre–1-HDL is formed by
apoA-I synthesized in the liver and intestine with the
addition of phospholipid. These delipidated HDL particles
pick up free cholesterol from cell membranes through the
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transporter to become discoidal 4-HDL. As this particle
atures, it accumulates more free cholesterol from the cells
including macrophages) through the ABCG1 transporter.
he free cholesterol is converted to cholesteryl ester by
ecithin cholesterol acyltransferase, which adds a fatty acid
rom phosphatidylcholine to free cholesterol, to form spher-
cal 3-HDL. Through the action of lipoprotein lipase on
triglyceride-rich lipoprotein, surface apolipoproteins are
transferred to HDL by cholesteryl ester transfer protein
(CETP), and triglyceride is transferred to HDL in exchange
for cholesteryl ester to form 2-HDL, which is further
nlarged to 1-HDL. Elevated 1-HDL or large HDL
articles are more likely associated with reduced cardiovas-
ular disease compared with other HDL lipoprotein sub-
ractions. Therefore, therapeutic approaches that increase
HDL may result in a greater cardiovascular benefit. The
1- and 2-HDL donates cholesteryl ester to the liver
through the scavenger receptor B1. Once in the liver,
cholesteryl ester is used for bile formation and secreted into
the intestine. A potential marker of enhanced reverse choles-
terol transport is an increase in fecal cholesterol (Fig. 1).
In animal models, increasing apoA transgenically or
infusing recombinant HDL promotes prominent regression
of atherosclerosis and enhanced macrophage-specific reverse
cholesterol transport. On the basis of these animal models,
this approach appears to offer the greatest clinical potential
for HDL-based therapies (7). There are also 3 intriguing
small human trials demonstrating that different approaches
to increasing lipid-poor apoA-I acceptors induce regression
of atherosclerosis in only 6 weeks in humans.
Figure 1 The Process of Reverse Cholesterol Transport
Discoidal pre–beta-high-density lipoprotein (HDL) is converted to spherical
alpha-HDL as cholesterol ester (CE) accumulates and is returned to the liver by
scavenger receptor B1 (SR-B1) or transfers the cholesteryl ester to apolipopro-
tein B lipoproteins by the cholesteryl ester transfer protein (CETP). ABCA1 
adenosine triphosphate-binding cassette-A1; A-I  apolipoprotein A-I; B  apoli-
poprotein B; FC  free cholesterol; LCAT  lecithin cholesterol acyltransferase;
LDL  low-density lipoprotein; LDLR  low-density lipoprotein receptor; TG 
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March 1, 2011:1120–1 ApoA-I TherapyThree small intravascular ultrasonography trials with
either apoA-I Milano, recombinant HDL, or delipidated
HDL infusion showed a similar 3.5% to 5% decrease in
atheroma volume compared with baseline, but owing to the
small sample sizes, these decreases were not statistically
significantly different from placebo (8–10).
An oral drug, RVX-208, selectively induces nuclear
transporter factors that increase hepatic and intestinal pro-
duction of apoA-I. In monkeys, this compound significantly
increased HDL-C by 40%, and the serum of treated
animals was shown to enhance cholesterol efflux from foam
cells (11). A small and short-term human trial demonstrated
significant increases in total plasma apoA-I, but most of the
increase was in pre–-HDL (11). This was the first oral
small molecule that stimulates apoA-I production to enter
phase II trials.
Unfortunately, the early promise of significant increase in
apoA-I levels in the monkeys was not replicated in this
phase II trial (12). There were only modest increases in
HDL-C and apoA-I (8.3% and 5.6%, respectively) at the
highest dose of RVX-208, which was also associated with an
unacceptable 10% rate of transaminase elevation (3 times
upper limit of normal). A potentially encouraging signal was
an approximately 20% increase in large HDL particles,
which suggests an improvement in reverse cholesterol trans-
port due to enhanced maturation to more lipid-rich HDL.
These modest changes in large HDL particles with RVX-
208 is less than can be achieved with niacin therapy (13).
Based on the disappointing efficacy of RVX-208, safety
issues due to transaminase elevations, and significant regu-
latory hurdles, major challenges lie ahead for the future
clinical development of this nuclear transcription factor for
increasing apoA levels. Hopefully, therapeutic approaches
to modulating apoA-I production will continue to progress
because the potential clinical benefits represent a major
unmet need in the treatment and prevention of cardiovas-
cular disease. The recent data regarding anacetrapib, a
CETP inhibitor in the DEFINE (Determining the Efficacy
and Tolerability of CETP Inhibition with Anacetrapib)
trial (14), while encouraging, is a very different approach to
affecting HDL metabolism, than enhancing apoA-I pro-
duction. Decreasing HDL catabolism through CETP inhi-
bition may not affect reverse cholesterol transport to nearly
the same magnitude as a potent stimulator of apoA-I
production. The promise of apoA-I therapy remains unful-
filled, and owing to the complex nature of HDLmetabolism
and a difficult regulatory pathway, there is an uncertain
future for one of the most highly sought targets for the
prevention and treatment of atherosclerosis.Reprint requests and correspondence: Dr. Michael H. David-
son, Preventive Cardiology, University of Chicago Pritzker
School of Medicine, 515 North State Street, Suite 2700,
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